- CA$22.04m
- CA$25.77m
- 10
- 30
- 69
- 29
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 10th, 2014
- Public Since
- December 20th, 2012
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 148,456,507
- Address
- 707 7th Ave. SW, Suite 1150, CALGARY, T2P 3H6
- Web
- https://hemostemix.com/
- Phone
- +1 9055804170
- Auditors
- MNP LLP
Upcoming Events for HEM
Hemostemix Inc Extraordinary Shareholders Meeting
Hemostemix Inc Annual Shareholders Meeting
Q2 2025 Hemostemix Inc Earnings Release
Similar to HEM
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
MustGrow Biologics
TSX Venture Exchange
FAQ
What is the Hemostemix share price?
As of Today at 03:04 UTC, shares in Hemostemix are trading at CA$0.10. This share price information is delayed by 15 minutes.
How has the Hemostemix share price performed this year?
Shares in Hemostemix last closed at CA$0.10 and the price had moved by +150% over the past 365 days. In terms of relative price strength the Hemostemix share price has outperformed the Toronto Stock Exchange 300 Composite Index by +116.25% over the past year.
What are the analyst and broker recommendations for Hemostemix?
The overall consensus recommendation for Hemostemix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Hemostemix dividend yield?
Hemostemix does not currently pay a dividend.
Does Hemostemix pay a dividend?
Hemostemix does not currently pay a dividend.
When does Hemostemix next pay dividends?
Hemostemix does not currently pay a dividend.
How do I buy Hemostemix shares?
To buy shares in Hemostemix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hemostemix?
As of the previous close price of CA$0.10, shares in Hemostemix had a market capitalisation of CA$14.10m.
Where are Hemostemix shares listed?
Here are the trading details for Hemostemix:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: HEM
What kind of share is Hemostemix?
Based on an overall assessment of its quality, value and momentum Hemostemix is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hemostemix share price forecast for 2025?
The analyst consensus target price for shares in Hemostemix is CA$0.96. That is 910.53% above the last closing price of CA$0.10.
Analysts covering Hemostemix currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Hemostemix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hemostemix. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +13.14%.
As of the last closing price of CA$0.10, shares in Hemostemix were trading -17.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hemostemix PE Ratio?
The Hemostemix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hemostemix?
Hemostemix's management team is headed by:
- Peter Lacey - NEC
- Thomas Smeenk - PRE
- Christina Wu - CFO
- Ronnie Hershman - IND
- Loran Swanberg - IND